Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It strictly details a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares via dividend reinvestment |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Date | July 14, 2016 |
| Transaction Price | £16.5875 per share |
| Total Volume | 58 shares |
| Total Value | £962.075 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records a routine acquisition of shares by Ms. S Witty, a PCA of CEO Sir Andrew Witty, following the reinvestment of dividends paid on July 14, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of a specific insider-related transaction.
Key Facts for Investor Verification
- The transaction involved the acquisition of 58 ordinary shares by a PCA of the CEO.
- The shares were acquired through a dividend reinvestment plan at a price of £16.5875.
- The transaction occurred on the London Stock Exchange on July 14, 2016.
- This filing does not contain quarterly or annual financial results.